World of DTC Marketing

JANUARY 8, 2021

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna. Supply Issues?

Vaccine 266

Vaccine Vaccination Pharma Companies Development 266

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccine 264

Vaccine Vaccination Genetics Trials 264

Pharmaceutical Technology

MARCH 3, 2025

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years old.

Vaccine 162

Vaccine Vaccination Marketing 162

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccine 52

Vaccine Vaccination RNA Development 52

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. Health experts have lent their support to the new programme as the existing vaccines may not be as effective against future virus threats.

Vaccine 264

Vaccine Vaccination Development Antibody 264

Pharmaceutical Technology

APRIL 13, 2023

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.

Production 279

Production Vaccine Vaccination Protein 279

World of DTC Marketing

DECEMBER 11, 2020

(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments.

Vaccine 227

Vaccine Vaccination Clinical Trials Clinical Trials 227

Pharmaceutical Technology

SEPTEMBER 21, 2023

The collaboration will use Evaxion’s EDEN platform to bring an AI-designed gonorrhea mRNA vaccine to the market.

Vaccine 246

Vaccine Vaccination Development Marketing 246

Bio Pharma Dive

JULY 24, 2023

The shot failed to meet a key goal of Bavarian Nordic’s Phase 3 study, a finding that separates it from marketed vaccines developed by Pfizer and GSK.

Vaccine 246

Vaccine Vaccination Marketing Development 246

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine 245

Vaccine Vaccination Development RNA 245

World of DTC Marketing

AUGUST 26, 2021

The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The bottom line is that we have to take bolder steps to get everyone vaccinated because the unvaccinated represent a danger to us all.

Vaccine 222

Vaccine Vaccination Contamination Regulation 222

Bio Pharma Dive

JULY 19, 2021

Approval of Merck's shot sets the stage for the two large pharmas to compete for market share with new pneumococcal vaccines that are meant to improve on older versions.

Vaccine 257

Vaccine Vaccination Marketing 257

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccination 289

Vaccination Vaccine Gene Therapy Manufacturing 289

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccine Vaccination Development 246

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree. “The

Vaccine 240

Vaccine Vaccination Production Life Science 240

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccine 245

Vaccine Vaccination Development Allergies 245

Pharmaceutical Technology

JULY 1, 2024

Valneva has secured marketing authorisation from the European Commission (EC) for IXCHIQ, a single-dose vaccine for preventing chikungunya.

Vaccine 147

Vaccine Vaccination Marketing 147

Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccine 363

Vaccine Vaccination Protein Clinical Trials 363

World of DTC Marketing

SEPTEMBER 10, 2021

The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. It is reckless at this point for the government not to mandate vaccination.

Vaccine 191

Vaccine Vaccination Licensing Licensing 191

Bio Pharma Dive

MAY 2, 2023

The drugmaker beat Wall Street’s first quarter forecasts despite a sales drop that puts pressure on it to succeed with upcoming market launches.

Sales 336

Sales Vaccination Vaccine Drugs 336

Pharmaceutical Technology

MARCH 26, 2025

Multinational companies in Chinas vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

Vaccine 147

Vaccine Vaccination Sales Marketing 147

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccine 195

Vaccine Vaccination Immune Response Bacteria 195

Pharmaceutical Technology

JUNE 8, 2023

The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and above. The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.

Vaccine 147

Vaccine Vaccination Marketing Manufacturing 147

Bio Pharma Dive

OCTOBER 29, 2024

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Vaccine 156

Vaccine Vaccination Sales Marketing 156

Bio Pharma Dive

OCTOBER 31, 2023

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Vaccine 171

Vaccine Vaccination Sales Marketing 171

Bio Pharma Dive

AUGUST 13, 2020

The biotech, which has quickly advanced its coronavirus shot to late-stage trials, raised nearly $750 million through the listing.

Marketing 252

Marketing Vaccination Vaccine Trials 252

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 287

Sales Vaccination Vaccine Production 287

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 265

Sales Marketing Vaccination Vaccine 265

Bio Pharma Dive

JANUARY 13, 2025

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Sales 300

Sales Vaccine Vaccination Marketing 300

Bio Pharma Dive

FEBRUARY 13, 2023

The company said its modified contract with the federal government, which comes ahead of a planned transition to private market sales, will help it develop an updated version of its vaccine.

Sales 339

Sales Vaccination Vaccine Marketing 339

Fierce Pharma

AUGUST 5, 2024

While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market.

Vaccine 136

Vaccine Vaccination Marketing 136

Bio Pharma Dive

JUNE 10, 2024

Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.

Vaccine 287

Vaccine Vaccination Trials Marketing 287

World of DTC Marketing

FEBRUARY 28, 2021

SUMMARY: Pharma companies, like J&J, have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses. Can a COVID-19 vaccine approval suddenly erase that? Johnson & Johnson has paid $2.7

Vaccine 180

Vaccine Vaccination Contamination Compliance 180

Fierce Pharma

MAY 8, 2024

On Tuesday, the EMA said it had accepted a request from AZ and withdrawn the company’s marketing authorization for its COVID-19 shot Vaxzevria.

Vaccine 128

Vaccine Vaccination Marketing Medicine 128

Pharmaceutical Technology

FEBRUARY 14, 2023

The US Department of Health and Human Services (HHS) and the Department of Defense have modified their existing agreement with Novavax to secure additional doses of the Covid-19 vaccine, Adjuvanted (NVX-CoV2373). million additional doses of its Covid-19 vaccine. Under the modified deal, Novavax will deliver up to 1.5

Vaccine 162

Vaccine Vaccination Protein Engineer 162

Pharmaceutical Technology

JUNE 28, 2024

The EMA's CHMP has recommended granting marketing authorisation for Pfizer and BioNTech’s Omicron JN.1-adapted 1-adapted Covid-19 vaccine.

Vaccine 147

Vaccine Vaccination Marketing 147

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Gene Therapy 351

Gene Therapy Vaccine Vaccination Manufacturing 351